ClinicalTrials.gg
RecruitingNCT07557706Updated Nov 16, 2026

Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease

A Phase 1 interventional study of transcutaneous auricular vagus nerve stimulation in PARKINSON DISEASE (Disorder), sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Alabama at Birmingham · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2025, registered Mar 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Parkinson Disease by University of Alabama at Birmingham — 8 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · University of Alabama at Birmingham.

Planned enrollment
15th of 20
24 · median 35
Started
2025
the only one that year
Phase 1
2 of 24
2 open now
Registered
22nd of 24
by date

Among the 24 studies in Parkinson Disease by University of Alabama at Birmingham, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1, and was the 22nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

8 of the 24 studies in Parkinson Disease by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Parkinson Disease by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.

03

Conditions studied

  • PARKINSON DISEASE (Disorder)

Browse trials for

Keywords

  • vagus nerve stimulation
  • neuromodulation
  • parkinson's disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of idiopathic PD
  • Stable medication for at least 4 weeks prior to the study

Exclusion criteria

Exclusion Criteria:

  • Use of beta blockers
  • Sustained severe hypertension (>/= 180/110 mmHg while seated)
  • Significant uncontrolled cardiac arrhythmia
  • Unstable angina
  • Congestive heart failure
  • History of myocardial infarction
  • History of seizures
  • Severe cognitive impairment
  • Pregnant women or women who are planning to become pregnant
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Group 1

    Active taVNS on Visit 2, Sham taVNS on Visit 3. Active taVNS is delivered at 30 Hz, 250 µs, 0.1-4 mA for 15 minutes. Sham taVNS is delivered at 0 mA output for 15 minutes. A minimum washout period of 48 hours will be observed between visits.

    Device: transcutaneous auricular vagus nerve stimulation

  • Experimental
    Group 2

    Sham taVNS on Visit 2, Active taVNS on Visit 3. Active taVNS is delivered at 30 Hz, 250 µs, 1-4 mA for 15 minutes. Sham taVNS is delivered at 0 mA output for 15 minutes. A minimum washout period of 48 hours will be observed between visits

    Device: transcutaneous auricular vagus nerve stimulation

Interventions

  • Devicetranscutaneous auricular vagus nerve stimulation

    Participants will sit quietly while receiving active nerve stimulation for 15 minutes. A gentle electrical current is delivered through hydrogel electrodes placed in the ear. The active stimulation parameters are set to 30 Hz, 250 µs, and 0.1-4 mA.

06

What researchers measure

Primary outcomes

  1. Change in heart rate

    Assessment of how the body adjusts heart rate during taVNS and during physical challenges. Tests include the Valsalva maneuver (blowing into a mouthpiece for 15 seconds), deep breathing test (breathing deeply and evenly at a rate of 6 breaths/minute), lying-to-standing heart rate and blood pressure tests, and an isometric handgrip test (sustaining a handgrip contraction on a dynamometer at 30% maximal effort for 5 minutes). Heart rate is continuously monitored using a Polar HR monitor.

    Time frame: During Visit 2 and Visit 3 (1-2 weeks after baseline, with 48 hour wash-out between visits 2 and 3), during and following 15 minutes of stimulation.

  2. Change in blood pressure

    Assessment of how the body adjusts blood pressure during taVNS and during physical challenges. Tests include the Valsalva maneuver (blowing into a mouthpiece for 15 seconds), deep breathing test (breathing deeply and evenly at a rate of 6 breaths/minute), lying-to-standing heart rate and blood pressure tests, and an isometric handgrip test (sustaining a handgrip contraction on a dynamometer at 30% maximal effort for 5 minutes). Blood pressure is measured manually using a sphygmomanometer.

    Time frame: During Visit 2 and Visit 3 (1-2 weeks after baseline, with 48 hour wash-out between visits 2 and 3), during and following 15 minutes of stimulation.

Secondary outcomes

  1. Skin temperature

    Infrared thermography will be used to assess facial, hand, and foot skin temperature.

    Time frame: Before, during and immediately after both active and sham taVNS.

  2. Autonomic Symptom Burden (COMPASS-31)

    The Composite Autonomic Symptom Score 31 (COMPASS-31) is a validated, self-assessment questionnaire used to evaluate the severity and distribution of autonomic nervous system symptoms.Scores from each domain are weighted and summed to calculate a final Total Score. The Total Score ranges from 0 to 100. A higher score indicates a greater severity and wider distribution of autonomic symptoms (worse autonomic function), while a lower score indicates fewer and less severe autonomic symptoms (better autonomic function).

    Time frame: Baseline (Visit 1)

  3. Autonomic Symptom Severity (SCOPA-AUT)

    The Scales for Outcomes in Parkinson's disease - Autonomic Dysfunction (SCOPA-AUT) is a self-administered questionnaire specifically developed to assess autonomic symptoms in individuals with Parkinson's disease. The questionnaire evaluates the frequency of problems experienced over the past month. Each item is scored on a 4-point Likert scale ranging from 0 ("never") to 3 ("often"). The Total Score is calculated by summing the responses of the 23 applicable items, with a possible range from 0 to 69. A higher score indicates a greater frequency and severity of autonomic dysfunction (worse autonomic functioning), while a lower score indicates fewer autonomic symptoms (better autonomic functioning).

    Time frame: Baseline (Visit 1)

  4. Physical Activity (Goodin Leisure-Time Exercise Questionnaire)

    The Godin Leisure-Time Exercise Questionnaire (GLTEQ) is a brief, validated self-report instrument that assesses an individual's usual physical activity habits over a typical 7-day period. The questionnaire consists of 3 items asking participants to report the number of times per week they engage in physical activities lasting more than 15 minutes across three specific intensity levels. The Weekly Leisure-Time Activity Score is calculated by multiplying the reported weekly frequencies by their respective Metabolic Equivalent (MET) values and summing the results using the following formula: (9 x Strenuous) + (5 x Moderate) + (3 x Light). The minimum possible score is 0, and there is no theoretical maximum upper limit. A higher score indicates a greater volume and intensity of weekly physical activity (better physical activity level). Clinically, a score of 24 or higher is classified as "Active," 14 to 23 as "Moderately Active," and less than 14 as "Insufficiently Active/Sedentary".

    Time frame: Baseline (Visit 1)

  5. Physical Activity (International Physical Activity Questionnaire)

    The International Physical Activity Questionnaire - Short Form (IPAQ-SF) is a validated self-report instrument used to estimate total physical activity and time spent sitting over the preceding 7 days. The questionnaire consists of 7 open-ended questions asking participants to recall the number of days per week and the amount of time usually spent per day engaged in specific intensities of physical activity lasting at least 10 minutes. Data are used to calculate the total physical activity expressed in Metabolic Equivalent of Task (MET)-minutes per week. The total MET-minutes/week is calculated by weighting the reported minutes per week for each activity category by a standard MET energy expenditure estimate (Walking = 3.3 METs, Moderate = 4.0 METs, Vigorous = 8.0 METs) and summing the values. The minimum possible score is 0, and there is no theoretical maximum upper limit. A higher MET-minutes/week score indicates a greater volume of physical activity.

    Time frame: Baseline (Visit 1)

07

Study locations

1 of 1 sites recruiting
  • Wellness, Health and Research Facility at UAB
    Birmingham, Alabama 35209, United States
    Recruiting
    • Alex Evancho · Contactamelgin@uab.edu · 205-975-5221
    • Alex Evancho, DPT, PhD · Principal investigator
08

References and documents

Publications

  • Barkoula TR, Ioannou C, Rekatsina M, Theodoraki K, Zis P. Cutoffs, sensitivity and specificity of the Ewing battery in evaluating autonomic nervous system disorders: a systematic review. Clin Auton Res. 2026 Apr;36(2):155-173. doi: 10.1007/s10286-025-01185-x. Epub 2026 Jan 20. PubMed 41557119 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.

Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 22 months is below that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Jul 2027 and completion Dec 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Apr 29, 2026
StartActual
Sep 15, 2025
Primary completionEst.
Jul 31, 2027was Aug 2026
CompletionEst.
Jul 31, 2027was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Jul 31, 2027
Nov 16, 2026
Study completion
Dec 31, 2026→Jul 31, 2027
Nov 16, 2026
Contact
Study contact changed: a•••@uab.edu · •••5221→a•••@uab.edu · •••5221. See the current contact
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Wellness, Health and Research Facility at UAB · Birmingham, United StatesContact person changed (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Aug 31, 2026→Jul 31, 2027
    Study completion Dec 31, 2026→Jul 31, 2027
    Contact Study contact changed: a•••@uab.edu · •••5221→a•••@uab.edu · •••5221. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Wellness, Health and Research Facility at UAB · Birmingham, United StatesContact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07557706
Responsible party
Alexandra Evancho (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Apr 29, 2026
Start date
Sep 15, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Alexandra Evancho, DPT, PhD
Contact
amelgin@uab.edu
205-975-5221

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion